I have worked in healthcare and life sciences for the past eighteen years. Therefore, I have spent a lot of time supporting the drug development process, covering discovery and development, preclinical research, clinical research and approvals.

As anyone in the industry will know, this process can take between ten to fifteen years, requiring significant investment.

In my previous article “Life Sciences AI”, I highlighted a few companies that are doing interesting things with technology, specifically Artificial Intelligence (AI), to support drug discovery and development. I also outlined the process (high level), providing basic insight into the different phases.

Earlier this month, NVIDIA hosted their annual GPU Technology Conference (GTC). There were many incredible sessions. However, the session “Toward Rational Drug Design With AlphaFold 3 and Beyond” from Isomorphic Labs resonated strongly with me.

As part of the talk, Max Jaderberg (Chief AI Officer) and Sergei Yakneen (Chief Technology Officer) from Isomorphic Labs shared how they develop general models of biology and translate these into real-world impact.

The talk itself is approximately 35 minutes long, with 10 minutes at the end for questions. If you are interested in healthcare and life sciences, computational science, and/or Artificial Intelligence (AI), it is well worth watching.

I am excited to see how these concepts can be applied to deliver the next generation of high-impact drugs to support human and animal health.

enterprise architecture ea enterprise_architecture artificial_intelligence ai machine_learning ml generative_ai large_language_model llm natural_language_processing nlp transformer data prompt_engineering life_sciences health healthcare nvidia gpu_technology_conference gtc isomorphic_labs lifeinwork